Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2018-06-29 Director's Dealing
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2018-06-29 English
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a public offering of common stock, including underwriting details and pricing. It also references press releases about the offering and the stock commencing trading on Nasdaq. There are no financial statements or detailed financial results presented, only disclosures about financing activities. This fits the definition of a Capital/Financing Update (CAP) rather than an Annual Report, Earnings Release, or other categories. The document length is about 5932 characters, which is sufficient for a substantive filing but it is clearly focused on financing activity. Therefore, the correct classification is CAP with high confidence.
2018-06-27 English
424B5 Filing
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a registration statement for a public offering of common stock. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and other disclosures typical of a capital raising document. It is not a financial report, earnings release, or management discussion. The presence of offering price, underwriting discounts, and share issuance details clearly indicate this is a capital/financing update document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual offering document, not just an announcement or a brief summary.
2018-06-26 English
424B3 Filing
Regulatory Filings Classification · 100% confidence The document is a Form 8-K current report filed with the SEC by Aerpio Pharmaceuticals, Inc. It details the entry into a material definitive agreement, specifically a License Agreement with Gossamer Bio, Inc. The content includes the terms of the license, milestone payments, royalties, and termination clauses. The document also includes a press release and the license agreement as exhibits. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is a regulatory filing reporting a significant corporate event (license agreement) rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS).
2018-06-25 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or material definitive agreements by a company. The text describes the entry into a material definitive agreement (a License Agreement) between Aerpio Pharmaceuticals and Gossamer Bio. It includes details about the agreement terms, payments, and termination clauses. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is not a proxy, call transcript, or governance report. It is a regulatory filing announcing a material contract event. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (6710 characters) and content confirm it is a full 8-K report, not just a brief announcement or certification.
2018-06-25 English
424B5 Filing
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement and accompanying prospectus related to an offering of common stock. It includes detailed information about the offering terms, risk factors, use of proceeds, underwriting, and other related disclosures. It references a shelf registration statement filed with the SEC and discusses securities offerings, underwriting discounts, and listing information. This type of document is a capital markets offering document, specifically a prospectus supplement, which falls under the category of Capital/Financing Update (CAP). It is not an annual report, earnings release, or any other report type but rather a financing update related to a securities offering.
2018-06-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.